secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2022-12-23T23:59:59+00:00
Accession:  0001563665-22-000019
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage Announces Publication Showing Rapid Esophageal Regeneration in Pigs
----------------------------------------------------------------------------

- Publication in Journal of Immunology and Regenerative Medicine describes regeneration after Biostage Esophageal Implant in nine pigs with full circumferential replacement.
- All animals regenerated a continuous biological conduit by 28 days; some as early as 14 days.
- Regeneration time compares favorably with FDA-approved clinical trial primary endpoint of 90 days.
- Biostage expects to initiate patient recruitment in first clinical trial in early 2023.
- Study also quantified epithelialization and fate of adipose-derived mesenchymal stromal cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/0001563665-22-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000156366522000019/tmb-20221223x8k.htm
  HTML page:      https://secwatch.observer/filing/0001563665-22-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer